Graphite Bio

Graphite Bio

  • Founded: 2020
  • Location: South SF, CA
  • Employee range: 50 - 200
  • Drug types: HEM, GEN, LNG
  • Lead product: GPH101
  • Product link:
  • Funding: $273M stock Jul 2021; $238M IPO Jun 2021; $150M B Mar 2021; $45M A Sep 2020
  • Investors: Versant Ventures

job board

Short description:

Next Generation Gene-Editing

Drug notes:

GPH102 RD Beta-Thalassemia; 2 add'l RD programs

Long description:

Graphite Bio is a gene-editing company developing therapeutics for a wide range of diseases. CRISPR technology offers the potential to rewrite genes and cure diseases following one therapeutic dose. Using their UltraHDR platform, Graphite is identifying CRISPR machinery that offers incredible precision in the gene-editing process and works to correct, replace and insert genes anywhere in the genome. Graphite’s proprietary technology has the potential to deliver individualized therapies going beyond personalized medicine. Currently, Graphite’s most advanced product, GPH101, is being tested to correct Sickle cell disease, with other programs focusing on Beta-thalassemia and AAT deficiency.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy